BIOMIMETIC THERAPEUTICS, INC. (BMTI) has 73 open-market insider trades by 11 insiders since 2006. The most active filer is A/s Novo, 10%.
| Name | Title | Tier | Trades | Value | Last Trade |
|---|---|---|---|---|---|
| A/s Novo | 10% | — | 33 | $26.0M | 2013-03-01 |
| Christopher B. Ehrlich | Dir | — | 2 | $8.0M | 2013-03-01 |
| Samuel Eugene Lynch | Pres | — | 14 | $5.5M | 2013-03-01 |
| Thomas Dyrberg | Dir10% | — | 1 | $4.2M | 2007-01-25 |
| Earl Martin Douglas | General Counsel | — | 6 | $420K | 2012-03-28 |
| Lawrence E. Bullock | CFO | — | 4 | $255K | 2013-03-01 |
| Gary E. Friedlaender | Dir | — | 5 | $205K | 2013-03-01 |
| Larry W. Papasan | Dir | — | 3 | $152K | 2013-03-01 |
| James G. Murphy | Dir | — | 2 | $46K | 2013-03-01 |
| Russell P. Pagano | VPReg. & Clinical Affairs | — | 2 | $37K | 2013-03-01 |
| Insider | Title | Type | Value | Date |
|---|---|---|---|---|
| Russell P. Pagano | VP & Reg. & Clinical Affairs | Sell | $11K | 2013-01-22 |
| Gary E. Friedlaender | Director | Buy | $28K | 2012-04-02 |
| Samuel Eugene Lynch | President | Buy | $169K | 2012-03-29 |
| Russell P. Pagano | VP & Reg. & Clinical Affairs | Sell | $8K | 2012-03-29 |
| Larry W. Papasan | Director | Buy | $17K | 2012-03-27 |
| Earl Martin Douglas | General Counsel | Sell | $126K |
Companies that share insiders with BMTI, and sector peers with recent insider buying. Related by who files, not by how the stocks move.
| 2012-03-26 |
| Samuel Eugene Lynch | President | Buy | $31K | 2012-03-23 |
| Gary E. Friedlaender | Director | Buy | $33K | 2012-03-19 |
| Lawrence E. Bullock | CFO | Buy | $44K | 2012-03-19 |
| Earl Martin Douglas | General Counsel | Sell | $27K | 2011-10-12 |
| Earl Martin Douglas | General Counsel | Sell | $36K | 2011-10-06 |
| Earl Martin Douglas | General Counsel | Sell | $26K | 2011-10-03 |
| Larry W. Papasan | Director | Sell | $37K | 2011-06-10 |
| Russell P. Pagano | VP & Reg. & Clinical Affairs | Buy | $15K | 2011-05-19 |
| Samuel Eugene Lynch | President | Buy | $102K | 2011-05-18 |